Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Triple Negative Breast Neoplasms 163Breast Neoplasms 162Neoplasm Metastasis 157Lung Neoplasms 147Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Endometrial Neoplasms 74Carcinoma, Hepatocellular 74Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Small Cell Lung Carcinoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

Rituximab 2CT-P10 2prednylidene 1pembrolizumab 1deltacortene 1Vincristine 1Prednisone 1Lenalidomide 1Doxorubicin 1Cyclophosphamide 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Composite Lymphoma × pembrolizumab × Clear all
NCT02541565 2020-10-14

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

University of Washington

Phase 1 Completed
30 enrolled 9 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡